JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Journal
Overview
publication venue for
- Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. 86:68-76. 2022
- Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. 86:77-85. 2022
- Dermatologic support for oncology: Quantifying the consultative services received by hospitalized oncology patients. 85:1367-1368. 2021
- National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. 84:1254-1268. 2021
- National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. 84:1254-1268. 2021
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. 83:1704-1716. 2020
- Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial. 82:1321-1327. 2020
- Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. 82:1314-1320. 2020
- Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. 81:923-930. 2019
- From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. 76:290-298. 2017
- Factors associated with biopsy site identification, postponement of surgery, and patient confidence in a dermatologic surgery practice. 74:1185-1193. 2016
- "Pretend you didn't hear that"--managing ethical dilemmas from the bottom of a medical hierarchy.. 74:766-8. 2016
- Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. 71:1167-1175. 2014
- From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. 70:178-186. 2014
- Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. 71:623-632. 2014
- Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. 71:633-641. 2014
- Research gaps in psoriasis: Opportunities for future studies. 70:146-167. 2014
- An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series. 68:255-261. 2013
- Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. 68:64-72. 2013
- Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. 68:262-269. 2013
- Orodental manifestations of facial port-wine stains. 67:687-693. 2012
- Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. 66:376-386. 2012
- Guidelines of care for the management of psoriasis and psoriatic arthritis. 65:137-174. 2011
- Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation. 65:537-545. 2011
- Phototherapy in dermatology: A call for action 2015
- Clascoterone in the treatment of mild hidradenitis suppurativa 2023
- Dermatology in the urgent care setting: A retrospective review of patients seen in an urgent access dermatology clinic 2023
- Clinical practice gaps in patients with extragenital lichen sclerosus: A retrospective review 2023
- Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial 2023
- Similar response to biologic therapy across racial and ethnic groups among patients with psoriasis enrolled in the CorEvitas Psoriasis Registry 2022
- From the Cochrane Library: Phototherapy for atopic eczema 2022
- From the Cochrane Library: Phototherapy for atopic eczema 2022
- From the Cochrane Library: Interventions for hand eczema 2022
- Response to: "Successful implementation of phototherapy guidelines during the COVID-19 pandemic" 2021
- Recommendations for phototherapy during the COVID-19 pandemic 2020
- Annual screening for tuberculosis in patients on TNF-alfa antagonists 2015
- Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors'' 2015
- Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis 2015
- The impact of psoriasis on 10-year Framingham risk 2012
- Recalcitrant herpetic scrotal ulcer as a manifestation of immune reconstitution inflammatory syndrome 2011
- In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: Risk or opportunity?" 2011
- Autoimmune Comorbidities and Antibody Markers Associated with Eosinophilic Fasciitis 2023
- Cutaneous T-cell Lymphoma and Dermatological Comorbidities: A National Cross-Sectional Study 2023
- Diabetes is associated with worse response to biologics at 12months among patients with plaque psoriasis in the CorEvitas Psoriasis Registry 2023
- Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials 2023
- Efficacy of a Virtual, State-Wide, Dermatology Advocacy Day in Promoting Advocacy Efforts amongst Medical Trainees 2023
- Efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa previously treated with biologic therapy: Week 16 results from the SUNSHINE and SUNRISE trials 2023
- Food Insecurity in People with Hidradenitis Suppurativa e Preliminary Results from A Cross Sectional Study 2023
- Spatial transcriptomic analysis of hidradenitis suppurativa dermal tunnels: A pilot study using digital spatial profiling highlights the invasive nature of hidradenitis tunnel epithelium 2023
- Steps for the Implementation of Virginia Dermatology Trainee Advocacy Day 2022: A State- Wide Conference for Healthcare Professionals and Medical Students to Increase Awareness and Advocate for Relevant Issues in Dermatology 2023
- Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2) 2022
- Efficacy of apremilast in patients with mild to moderate psoriasis assessed by the physician global assessment and body surface area composite tool: Post hoc analysis from ADVANCE 2022
- Hidradenitis suppurativa and dermatologic comorbidities in adults: A national-cross sectional study 2022
- Improvement in disease severity and quality of life in patients with atopic dermatitis (AD) treated with dupilumab for up to 18 months: Real-world evidence from the PROSE registry 2022
- Skin cancer screening practices among dermatologists: A survey study 2022
- Achievement of body surface area treatment targets in clinical trials of brodalumab 2021
- Cardiac autonomic dysfunction in psoriasis patients with and without metabolic syndrome 2021
- Characteristics of patients with psoriasis differ by obesity status and history of metabolic comorbidities 2021
- Dupilumab with topical corticosteroids results in rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across all anatomic regions over 52 weeks 2021
- Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: Real-world data from the PROSE registry 2021
- Effectiveness of guselkumab among patients with moderate-to-severe plaque psoriasis in the Corrona Psoriasis Registry 2021
- Impact of guselkumab on quality of life and work productivity outcomes among patients with moderate-to severe plaque psoriasis in the Corrona Psoriasis Registry 2021
- Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study 2021
- Improvements and response achievement in PASI subscale domains for head scaling and erythema in apremilast-treated patients with moderate to severe plaque psoriasis of the scalp: Results from the STYLE study 2021
- Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial 2021
- Pharmacokinetic analyses show limited systemic exposure with topical glycopyrronium tosylate 2021
- Roflumilast cream significantly improves chronic plaque psoriasis in patients with steroid-sensitive area involvement 2021
- The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor 2021
- 2018 geographic variations in the use of biologic therapy for psoriasis in the Corrona Psoriasis Registry 2020
- Assessment of physiologic and perceptual barriers to physical activity in patients with psoriasis: A pilot study 2020
- Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis 2020
- Predictors of satisfaction among patients with psoriatic disease: An analysis and visualization of the 2016 and 2017 National Psoriasis Foundation Annual Survey 2020
- Response to treatment with secukinumab in obese patients with moderate to severe psoriasis 2020
- Sun protection behaviors among active members of the United States Lifesaving Association 2020
- A real-world view of biologic use in psoriatic disease: A pilot GIS analysis of the 2016 and 2017 NPF national survey 2019
- An evaluation of anticholinergic adverse events with long-term use of glycopyrronium cloth, a treatment for primary axillary hyperhidrosis 2019
- Dupilumab for adolescents with moderate-to-severe atopic dermatitis: Results from a phase 3, randomized, double-blinded trial 2019
- Efficacy and safety of difamilast, a topical PDE4 inhibitor, in a phase 2 study of pediatric patients with atopic dermatitis 2019
- Glycopyrronium cloth improves axillary hyperhidrosis across a broad spectrum of patients: Post hoc analyses of the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials in patient subpopulations 2019
- Individually we are good, but together we could be great: Exploring multidisciplinary surgical training for dermatology residents 2019
- Long-term efficacy of glycopyrronium cloth in patients with primary axillary hyperhidrosis 2019
- Persistent reduction of response to secukinumab is uncommon in plaque psoriasis patients: A pooled analysis of FIXTURE and CLEAR 2019
- Voice of the hyperhidrosis patient: Symptoms, impacts & treatments, insights from large, open FDA-attended meeting 2019
- A case of accentuated delusions in a patient with schizophrenia treated with topical clobetaso 2018
- Characterization of nonresponders to anti-TNFs in moderate-to-severe psoriasis patients in routine clinical practices in the US 2018
- Patient profile of nonresponders to ustekinumab in moderate-to-severe psoriasis patients enrolled in the Corrona Psoriasis Registry 2018
- Psoriasis patients achieving National Psoriasis Foundation Treat-to-Target goals and associated quality of life improvement in the Corrona Psoriasis Registry cohort 2018
- Symptom relapse following apremilast discontinuation is related to longer disease duration at treatment initiation in patients with moderate-to-severe psoriasis 2018
- Research objectives and design of the Corrona Psoriasis Registry: A large prospective cohort of psoriasis patients in the United States 2016
- A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation 2019
- Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation 2018
- Psoriasis and comorbid diseases Epidemiology 2017
- Psoriasis and comorbid diseases Implications for management 2017
- From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis 2016
- From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies 2014
- From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis 2013
- Review of treatment options for psoriasis in pregnant or lactating women: From the Medical Board of the National Psoriasis Foundation 2012
- Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation 2012
- Guidelines of care for the management of psoriasis and psoriatic arthritis Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy 2010
- Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation 2010
- Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation 2010
- Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation 2010
Identity
International Standard Serial Number (ISSN)
- 0190-9622
Electronic International Standard Serial Number (EISSN)
- 1097-6787